CML Highlights of EHA 2024

Clinical Highlights

Expert

Professor Andreas Hochhaus
Director of the Department of Hematology and Medical Oncology
Jena University Hospital (Germany)

00:00 Welcome and introduction
02:01 Treatment optimisation in CML (Hochhaus EHA 2024)
03:25 Line-agnostic treatment recommendations according to clinical and biological data
04:38 Asciminib first-line ASC4 First (Hochhaus et al, EHA 2024)
09:21 Dasatinib dose optimisation - DasaHit (La Rosée P et al., EHA 2024)
12:30 Ponatinib dose optimisation - OPTIC (Apperley J et al., EHA 2024)
14:21 Ponatinib and azacytidine in myeloid blast phase (Rousselot P et al., EHA 2024)

Biological Highlights

Expert

Professor Nick Cross
Professor of Human Genetics at the University of Southampton
Southampton (UK)

00:00 Introduction
Prediction of DMR/TFR
01:17 Abstract S167: A novel immune-related score predicts deep molecular response in chronic-phase CML treated upfront with TKIs
03:19 Abstract S166: A machine-learning approach identifies a 27-genes transcriptome signature predicting TFR in CML
05:32 Abstract S169: A novel CIP2A and BCL-XL clinical diagnostic toolkit to predict disease progression and TFR in CML

Outcome and treatment of blast crisis
07:14 Abstract S165: Development of a prognostic scroring system for CML in blast phase: Insights from the European LeukemiaNet Blast Phase Registry
08:42 Abstract P706: Design and validation of mass cytometry apoptotic panel for predicting sensitivity of CML blast cells cross-resistant to TKIs to the BCL2 inhibitor venetoclax
11:38 Abstract S168: Combinatory therapy of ponatinib and venetoclax was effective in the treatment of asciminib-resistant CML in vivo

New therapeutic approaches
12:29 Protac inhibitors of BCR::ABL1
16:29 Potential for stem cell inhibition in CML

20:01 Q&A Session